A novel human parathyroid hormone (1-34) analog for the treatment of osteoporosis

Peptides ◽  
2009 ◽  
Vol 30 (6) ◽  
pp. 1173-1180 ◽  
Author(s):  
Jiao Feng ◽  
Yanhua Liu ◽  
Yun Xing ◽  
Huaqian Wang ◽  
Taiming Li ◽  
...  
2008 ◽  
Vol 1 ◽  
pp. CCRep.S1026 ◽  
Author(s):  
Terje Forslund ◽  
Anna-Mari Koski ◽  
Arvo Koistinen ◽  
Anu Sikiö

A breakthrough in understanding of mechanisms of bone structure regulation has brought about the introduction of the new synthetic recombinant human parathyroid hormone 1–34 (PTH1-34; Teriparatide) in the treatment of osteoporosis. These mechanisms, involving the RANKL, RANK, and osteoprotegerin system, are also known to be involved in malignant myeloma (MM) and tumor and bone metastasis development. We report a case in which MM was found after treatment of osteoporosis with teriparatide. We were unable to demonstrate any direct association between the MM and teriparatide treatment. However, it seemed intriguing that similar mechanisms are activated in the development of MM as those being working during teriparatide treatment. In the view of our case, we propose that MM by examination of serum protein fraction should be searched for prior to treatment with teriparatide as it is an exclusion criterion in teriparatide treatment of secondary osteoporosis. A search for other metastatic diseases prior to teriparatide treatment should eventually also be considered. The theoretical basis for our proposal is discussed.


1976 ◽  
Vol 50 (2) ◽  
pp. 14P-14P
Author(s):  
J. Reeve ◽  
J. A. Parsons ◽  
G. W. Tregear ◽  
A. J. Darby ◽  
R. Hesp ◽  
...  

2001 ◽  
Author(s):  
Lisa M. Waldegger ◽  
Ann Cranney ◽  
Jonathan Adachi ◽  
Peter Tugwell ◽  
George A Wells

2004 ◽  
Vol 94 (6) ◽  
pp. 260-270 ◽  
Author(s):  
Kim T. Brixen ◽  
Brixen Christensen ◽  
Charlotte Ejersted ◽  
Bente Lomholt Langdahl

Pharmaceutics ◽  
2018 ◽  
Vol 10 (4) ◽  
pp. 215 ◽  
Author(s):  
Chihiro Naito ◽  
Hidemasa Katsumi ◽  
Tomoko Suzuki ◽  
Ying-shu Quan ◽  
Fumio Kamiyama ◽  
...  

Human parathyroid hormone (1-34) (PTH) has been widely used as the subcutaneous injection formulation for the treatment of osteoporosis. In the present study, we developed an efficient transdermal delivery system of PTH by using dissolving microneedle arrays (MNs) composed of hyaluronic acid (HA) for the treatment of osteoporosis. PTH-loaded MNs, with needle length 800 µm, were fabricated via a micro-molding method. The stability of PTH in MNs was found to be 6-fold higher than that of PTH solution when stored at room temperature (15–20 °C) for one month. Micron-scale pores were clearly visible in rat skin following application of PTH-loaded MNs. PTH-loaded MNs were completely dissolved by 60 min following application to rat skin. The bioavailability (BA) of PTH relative to subcutaneous injection was 100 ± 4% following application of PTH-loaded MNs in rats. In addition, PTH-loaded MNs were found to effectively suppress decreases in bone density in a rat model of osteoporosis. Furthermore, no skin irritation was observed at the site of application in rats. These findings indicate that our dissolving MNs have a potential use in formulations for the transdermal delivery of PTH and for the treatment of osteoporosis.


Sign in / Sign up

Export Citation Format

Share Document